anmelden
Novartis Aktie
125,50
EUR
-0,32
EUR
-0,25
%
125,54
EUR
-0,46
EUR
-0,37
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 235,06 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 27.11.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 21.11.12 | Novartis reduce | Vontobel Research | |
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Novartis buy | Sarasin Research | |
| 16.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 15.11.12 | Novartis buy | UBS AG | |
| 15.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 12.11.12 | Novartis outperform | Credit Suisse Group | |
|
Werbung
|
|||
| 08.11.12 | Novartis reduce | Vontobel Research | |
| 08.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 07.11.12 | Novartis reduce | Vontobel Research | |
| 06.11.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 05.11.12 | Novartis neutral | Citigroup Corp. | |
| 02.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 30.10.12 | Novartis buy | Deutsche Bank AG | |
| 29.10.12 | Novartis halten | Independent Research GmbH | |
| 29.10.12 | Novartis outperform | Credit Suisse Group | |
| 26.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 26.10.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 26.10.12 | Novartis reduce | Vontobel Research | |
| 25.10.12 | Novartis buy | Sarasin Research | |
| 25.10.12 | Novartis reduce | Vontobel Research | |
| 24.10.12 | Novartis underperform | Cheuvreux SA | |
| 24.10.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 23.10.12 | Novartis buy | Nomura | |
| 19.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 17.10.12 | Novartis reduce | Vontobel Research | |
| 17.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 16.10.12 | Novartis neutral | Citigroup Corp. | |
| 16.10.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
| 16.10.12 | Novartis outperform | Credit Suisse Group | |
| 12.10.12 | Novartis outperform | Credit Suisse Group | |
| 12.10.12 | Novartis buy | Nomura | |
| 12.10.12 | Novartis reduce | Vontobel Research | |
| 12.10.12 | Novartis buy | UBS AG | |
| 11.10.12 | Novartis buy | Deutsche Bank AG | |
| 11.10.12 | Novartis buy | UBS AG | |
| 08.10.12 | Novartis halten | Independent Research GmbH | |
| 08.10.12 | Novartis reduce | Vontobel Research | |
| 04.10.12 | Novartis buy | Nomura | |
| 01.10.12 | Novartis buy | Sarasin Research | |
| 01.10.12 | Novartis reduce | Vontobel Research | |
| 24.09.12 | Novartis reduce | Vontobel Research | |
| 24.09.12 | Novartis buy | Sarasin Research | |
| 13.09.12 | Novartis reduce | Vontobel Research | |
| 12.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 11.09.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
| 11.09.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 07.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 06.09.12 | Novartis neutral | Exane-BNP Paribas SA | |
Werbung
Werbung
